Sunday 18 October 2026 Export FEED’s income statement to Excel — free account

ENvue Medical, Inc.

ENvue Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue fell 51.6%, EPS grew 75.8%, free cash flow grew 19.8% and total debt fell 45.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.37 0.12 −24.49%

Follow FEED

Alert me

Market cap: $950.0K
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 2/9
Altman Z: −4.72
Beneish M: 6.64
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.64

Total sells 0.15

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	1	—	—	—	—	—	—	—	—	—
Sell	—	—	—	1	—	—	—	1	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 0.95

Revenue 1.93

Net Income (21.06)

Free Cash Flow (11.74)

Net Debt (0.06)

Current Ratio 0.66

Debt/Equity 0.04

P/E ratio 0.00

Fwd P/E (1.31)

P/S ratio 0.10

P/B ratio 0.01

Past 5Y EPS Growth —

This Y EPS Growth 44.70%

Next Y EPS Growth —

Next Y revenue growth (55.75%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.18%

10-year low 10-year high

P/B against its own 10 years 0.24%

10-year low 10-year high

EV/Sales against its own 10 years 0.60%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	1	4	1
Receivables	0	0	0	0
Inventory	3	2	2	3
Other	—	—	—	—
	6	3	7	5

	2023	2024	2025	Q'26
Payables	2	1	3	4
ST’ Debt	—	—	1	1
Other	—	—	—	—
	2	3	7	7

Compound Annual Growth %

	10y	5y	3y
Sales	33.04%	32.59%	50.29%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	69.50%	118.01%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	0	—	—	—
’25	1	0	1	0	3
’24	1	1	0	0	3
’23	0	0	0	1	2
’22	0	0	0	0	1
’21	0	0	0	1	2
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(1)	(3)	(2)	(3)	(9)
’24	(1)	(1)	(1)	(1)	(3)
’23	(1)	(1)	(1)	0	(4)
’22	(2)	(2)	(2)	(1)	(7)
’21	(1)	(2)	(1)	(1)	(4)
’20	(1)	0	(1)	(1)	(3)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(3)	—	—	—
’25	(1)	(3)	(2)	(3)	(9)
’24	(1)	(1)	(1)	(1)	(3)
’23	(1)	(1)	(1)	0	(4)
’22	(2)	(2)	(2)	(1)	(7)
’22	—	—	—	—	(7)
’21	(1)	(2)	(1)	(1)	(4)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(82.59)	(23.77)	—	—	—
’25	(356.71)	(98.29)	(10.92)	100.25	(320.41)
’24	(303.76)	(330.17)	(42.79)	(988.36)	(1.65k)
’23	(884.84)	(858.43)	(554.68)	(515.05)	(2.80k)
’22	(1.06k)	(1.32k)	(792.40)	(1.87k)	(5.07k)
’21	(5.37k)	(264.13)	(6.87k)	(2.63k)	(14.99k)
’20	(3.43k)	(5.28k)	(2.64k)	244.55	(11.10k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	87,120.00	97,152.00	74,184.00	51,744.00	14,124.00	17,952.00	5,808.00	957.00	600.60	25.08	Analyst estimates 2026–2028 Powerpack
	High	224,400.00	193,248.00	132,000.00	118,800.00	92,400.00	110,616.00	35,904.00	10,032.00	2,006.40	1,950.00
People
People	Employees	10	12	10	14	12	16	14	16	31	14
	Revenue/emp, $m	0.02	0.02	0.03	0.04	0.05	0.11	0.05	0.14	0.08	0.18
Income, $m
Income, $m	Revenue	0	0	0	1	1	2	1	2	3	3
	Gross margin, %	61.57	63.18	50.31	53.02	34.35	45.43	22.21	67.32	58.95	5.99
	EBT	(3)	(5)	(4)	(6)	(4)	(14)	(5)	(4)	(4)	(18)
	EBT margin, %	(1,185.15)	(2,061.51)	(1,346.23)	(1,096.42)	(691.97)	(840.71)	(719.81)	(161.28)	(144.10)	(724.32)
	Net income	(3)	(5)	(4)	(6)	(4)	(14)	(5)	(4)	(4)	(18)
	Depreciation	0	1	0	0	0	0	0	0	0	12
Per share, $
Per share, $	Revenue	1,145.00	1,195.00	1,590.00	1,766.67	1,557.50	1,695.00	683.64	1,756.15	1,162.73	48.81
	Earnings	(16,376.18)	(30,903.46)	(16,904.45)	(21,922.95)	(10,677.07)	(15,048.94)	(5,071.33)	(2,799.80)	(1,648.26)	(320.41)
	Cash flow	(7,665.00)	(10,910.00)	(17,750.00)	(12,913.33)	(8,477.50)	(4,367.00)	(6,395.45)	(2,770.77)	(1,143.64)	(179.20)
	Capex	(40.00)	0.00	(40.00)	0.00	(5.00)	(3.00)	(2.73)	(0.77)	(1.36)	(1.15)
	Free cash flow	(7,705.00)	(10,910.00)	(17,790.00)	(12,913.33)	(8,482.50)	(4,370.00)	(6,398.18)	(2,771.54)	(1,145.00)	(180.34)
	Book value	(12,495.00)	18,170.00	2,315.00	4,493.33	5,985.00	6,313.00	2,939.09	3,067.69	285.00	640.48
	Shares, m	0	0	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	138.34	99.86	60.12	42.59	12.95	16.20	8.88	0.86	0.67	0.57
	P/B	0.00	6.57	41.47	16.79	3.37	4.35	2.07	0.49	2.73	0.04
	EV/Sales	144.43	93.72	66.41	43.06	0.92	11.68	5.35	(0.55)	0.39	(0.66)
	EV/FCF	(21.46)	(10.26)	(5.93)	(5.88)	(0.17)	(4.53)	(0.57)	0.35	(0.40)	0.18
Cash, $m
Cash, $m	Operating cash flow	(2)	(2)	(4)	(4)	(3)	(4)	(7)	(4)	(3)	(9)
	Capex	0	—	0	—	0	0	0	0	0	0
	Free cash flow	(2)	(2)	(4)	(4)	(3)	(4)	(7)	(4)	(3)	(9)
Balance, $m
Balance, $m	Working capital	0	4	1	1	5	6	3	4	1	1
	Total debt	—	—	—	—	0	0	0	—	—	1
	Net debt	0	(4)	(1)	(1)	(8)	(8)	(3)	(3)	(1)	(3)
	Shareholders’ equity	(2)	4	0	1	2	6	3	4	1	33
Returns, %
Returns, %	ROA	(228.58)	(216.68)	(128.91)	(320.46)	(84.29)	(169.51)	(75.14)	(59.13)	(71.92)	(74.97)
	ROIC	0.00	0.00	0.00	(32,193.75)	0.00	0.00	(602.40)	(304.61)	0.00	(47.18)
	ROE	208.78	(1,026.70)	(202.98)	(641.99)	(231.58)	(328.13)	(114.14)	(102.78)	(160.56)	(98.32)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VJET Flyte Aviation, Inc.	$2.1M	— (loss-making)	— (loss-making)	+380.66% (above 0%: growing)	n/m	−26.70% (below 0%: shrinking)	9.62%	(388.13%)	Compare
NUWE Nuwellis, Inc.	$2.0M	— (loss-making)	— (loss-making)	+14.14% (above 0%: growing)	n/m	−51.55% (below 0%: shrinking)	76.08%	(160.94%)	Compare
AFIB Acutus Medical, Inc.	$1.7M	— (loss-making)	— (loss-making)	+204.18% (above 0%: growing)	n/m	+76.40% (above 0%: growing)	14.20%	(3.81%)	Compare
DHAI DIH Holding US, Inc.	$1.6M	— (loss-making)	—	−30.67% (below 0%: shrinking)	n/m	−167.90% (below 0%: shrinking)	50.33%	(33.62%)	Compare
DYNTQ Dynatronics Corporation	$1.2M	— (loss-making)	— (loss-making)	−7.61% (below 0%: shrinking)	n/m	−193.04% (below 0%: shrinking)	24.65%	(1.26%)	Compare
THMO ThermoGenesis Holdings, Inc.	$1.1M	— (loss-making)	5.5×	+6.42% (above 0%: growing)	n/m	+62.12% (above 0%: growing)	43.92%	(20.35%)	Compare
SSKN Strata Skin Sciences, Inc.	$1.0M	— (loss-making)	— (loss-making)	−2.97% (below 0%: shrinking)	n/m	−376.88% (below 0%: shrinking)	61.82%	7.66%	Compare
FEED ENvue Medical, Inc.	$950.0K	— (loss-making)	— (loss-making)	−51.62% (below 0%: shrinking)	n/m	+19.75% (above 0%: growing)	(111.30%)	(2,290.38%)
PFSA PROFUSA, Inc.	$650.0K	0.0×	—	—	n/m	−359.25% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$1.4M	—	—	+6.42%	—	−109.72%	47.12%	(12.08%)

All 149 Medical Devices stocks →